CO2023008648A2 - Tratamiento de trastornos asociados con baja biodisponibilidad de bh4 - Google Patents
Tratamiento de trastornos asociados con baja biodisponibilidad de bh4Info
- Publication number
- CO2023008648A2 CO2023008648A2 CONC2023/0008648A CO2023008648A CO2023008648A2 CO 2023008648 A2 CO2023008648 A2 CO 2023008648A2 CO 2023008648 A CO2023008648 A CO 2023008648A CO 2023008648 A2 CO2023008648 A2 CO 2023008648A2
- Authority
- CO
- Colombia
- Prior art keywords
- low bioavailability
- disorders associated
- treatment
- disorders
- mthf
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 abstract 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 abstract 2
- 235000007635 levomefolic acid Nutrition 0.000 abstract 2
- 239000011578 levomefolic acid Substances 0.000 abstract 2
- 201000011252 Phenylketonuria Diseases 0.000 abstract 1
- 230000037354 amino acid metabolism Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 229960004617 sapropterin Drugs 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere al uso de un folato reducido, como el 5-MTHF (5-metiltetrahidrofolato), opcionalmente en combinación con tetrahidrobiopterina (BH4) o precursores del mismo, para prevenir o tratar trastornos asociados con una deficiencia de BH4, o baja biodisponibilidad de BH4. Tales trastornos incluyen principalmente enfermedades que tienen patología endotelial vascular o efectos sobre el metabolismo o la neurotransmisión de aminoácidos, especialmente trastornos relacionados con el embarazo, como la preeclampsia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020285.9A GB202020285D0 (en) | 2020-12-21 | 2020-12-21 | Treatment od disorders associated with loww BH4 bioavailablility |
| GBGB2108231.8A GB202108231D0 (en) | 2021-06-09 | 2021-06-09 | Treatment of disorders associated with low bh4 bioavaliability |
| PCT/GB2021/053382 WO2022136851A1 (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023008648A2 true CO2023008648A2 (es) | 2023-07-31 |
Family
ID=79283018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0008648A CO2023008648A2 (es) | 2020-12-21 | 2023-06-29 | Tratamiento de trastornos asociados con baja biodisponibilidad de bh4 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4262806A1 (es) |
| JP (1) | JP2024502252A (es) |
| KR (1) | KR20230124967A (es) |
| AU (1) | AU2021406035A1 (es) |
| CA (1) | CA3202619A1 (es) |
| CL (1) | CL2023001821A1 (es) |
| CO (1) | CO2023008648A2 (es) |
| IL (1) | IL303773A (es) |
| MX (1) | MX2023007167A (es) |
| WO (1) | WO2022136851A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544994B2 (en) * | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
| US20080064702A1 (en) * | 2006-09-08 | 2008-03-13 | Charalambos Antoniades | Use of folates for the prevention and treatment of vascular diseases |
| US20100009997A1 (en) * | 2007-01-12 | 2010-01-14 | Biomarin Pharmaceutical Inc. | Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug |
| WO2008137043A1 (en) * | 2007-05-02 | 2008-11-13 | South Alabama Medical Science Foundation | Methods and compositions |
| US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN105106217B (zh) * | 2015-08-13 | 2018-08-28 | 李健 | 一种孕妇营养补充剂及其制备方法 |
-
2021
- 2021-12-21 CA CA3202619A patent/CA3202619A1/en active Pending
- 2021-12-21 EP EP21839631.5A patent/EP4262806A1/en active Pending
- 2021-12-21 AU AU2021406035A patent/AU2021406035A1/en active Pending
- 2021-12-21 JP JP2023537676A patent/JP2024502252A/ja active Pending
- 2021-12-21 KR KR1020237024218A patent/KR20230124967A/ko unknown
- 2021-12-21 WO PCT/GB2021/053382 patent/WO2022136851A1/en active Application Filing
- 2021-12-21 IL IL303773A patent/IL303773A/en unknown
- 2021-12-21 MX MX2023007167A patent/MX2023007167A/es unknown
-
2023
- 2023-06-19 CL CL2023001821A patent/CL2023001821A1/es unknown
- 2023-06-29 CO CONC2023/0008648A patent/CO2023008648A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL303773A (en) | 2023-08-01 |
| KR20230124967A (ko) | 2023-08-28 |
| MX2023007167A (es) | 2023-06-29 |
| EP4262806A1 (en) | 2023-10-25 |
| JP2024502252A (ja) | 2024-01-18 |
| AU2021406035A1 (en) | 2023-06-22 |
| CA3202619A1 (en) | 2022-06-30 |
| CL2023001821A1 (es) | 2024-03-08 |
| WO2022136851A9 (en) | 2023-07-20 |
| WO2022136851A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| CY1124519T1 (el) | ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΚΑΙ ΦΑΡΜΑΚΟΤΕΧΝΙΚΕΣ ΜΟΡΦΕΣ ΤΟΥ (S)-4-(8-ΑΜΙΝΟ-3-(1-(ΒΟΥΤ-2-ΥΝΟΫΛΟ)ΠΥΡΡΟΛΙΔΙΝ-2-ΥΛΟ) ΙΜΙΔΑΖΟ[1,5-α|ΠΥΡΑΖΙΝ-1-ΥΛΟ)-Ν-(ΠΥΡΙΔΙΝ-2-ΥΛΟ) ΒΕΝΖΑΜΙΔΙΟΥ | |
| UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| CO6612228A2 (es) | Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer | |
| BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
| BR112012007234A2 (pt) | combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação | |
| BR112015005862A2 (pt) | derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| DOP2012000250A (es) | COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO | |
| PH12020500190A1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases | |
| BR112015006524A8 (pt) | derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit) | |
| CO6341543A2 (es) | Composiciones mucoadherentes y sus usos | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| TN2017000258A1 (en) | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors | |
| BR112014004879A2 (pt) | uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas | |
| BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
| BR112015006363A2 (pt) | combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r | |
| BR112014009242A8 (pt) | nanossuspensão farmacêutica | |
| CR20160055A (es) | Composiciones tópicas para el tratamiento de sudoración excesiva y métodos para utilizar las mismas |